Lipisiran™ cardiovascular in vitro study completed
Summary by AI BETAClose X
11 November 2026
Thalia Therapeutics plc
("Thalia" or the "Company")
Successful completion of Lipisiran™ cardiovascular in vitro study
Positive gene silencing results support progression into in vivo studies
Thalia Therapeutics plc (AIM: THAT), a clinical-stage biotechnology company developing innovative RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease, announces that it has successfully completed an in vitro study for its gene silencing cardiovascular risk reduction programme, THAT-002, achieving the target objectives that enable it to advance to in vivo studies. The THAT-002 programme will now be known as Lipisiran™.
Lipisiran™ is being developed as a potentially long-duration, dual-acting siRNA therapeutic targeting both PCSK9 and lipoprotein(a) (“Lp(a)”), two independent drivers of cardiovascular disease risk. Thalia’s objective is to develop a single therapeutic agent that addresses both targets to reduce global cardiovascular risk of heart attack and stroke. The long-duration impact is intended to improve patient compliance and therapeutic efficacy.
The in vitro study in human liver cells was designed to determine whether Thalia’s bispecific siRNA constructs could lower levels of both PCSK9 and Lp(a) in the target cells. All four constructs tested showed positive results, indicating engagement with the therapeutic targets.
The study also showed that Thalia’s bispecific siRNA constructs lowered both PCSK9 and Lp(a) as effectively as when the individual siRNA sequences were treated separately.
Following these successful in vitro outcomes, the Company has commenced a series of in vivo studies for Lipisiran™ to establish efficacy and durability.
Dr David Solomon, Chief Executive Officer of Thalia, commented:
“We are greatly encouraged by these in vitro results that see the evolution of the concept of THAT-002 to the beginnings of a potential product in Lipisiran™ with the goal of reducing the global risk of heart attack and stroke.
“Showing that our bispecific constructs can lower the targets PCSK9 and Lp(a) as effectively as the individual siRNA sequences is a significant step forward in validating our thesis as to the merits of a long-duration, dual-acting siRNA therapeutic to address the huge cardiovascular disease market. The proposed acquisition of Silence Therapeutics, a former AIM-listed company, by Merck KGaA for an equity value of approximately US$1.3 billion, which also has a mono Lp(a) gene silencing medicine, highlights the significant interest in effective next-generation siRNA medicines.
“We have now begun our in vivo studies, and I look forward to providing updates as and when appropriate and, in doing so, determining the next investment and development steps as we seek to advance Lipisiran™.”
- Ends -
For more information please contact:
|
Thalia Therapeutics plc Dr David H Solomon, Chief Executive Officer |
Via Thalia Investor Hub |
|
SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Jen Clarke (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) |
Tel: +44 (0)20 3470 0470 |
|
Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker/Guy McDougall |
Tel: +44 (0)20 3657 0050 |
|
Northstar Communications Limited Investor relations and Communications Sarah Hollins
Cohesion Bureau Investor relations and Communications Mary-Ann Chang |
Tel: +44 (0)20 7183 2463
Tel: +44 (0)7483 284853
|
About Thalia Therapeutics plc
Thalia Therapeutics is a clinical-stage biotechnology company developing innovative RNA-based therapeutics and delivery technologies across oncology and cardiovascular disease. With a growing, differentiated pipeline, de-risked by validated therapeutic targets, we aim to treat disease at its source by silencing or modifying the genes that cause or contribute to it.
Our clinical-stage programme miRisten (THAT-001) is a microRNA therapeutic in development for Acute Myeloid Leukaemia (AML). Alongside this, our preclinical bispecific siRNA Lipisiran™ (THAT-002) is being developed as a potential long-acting treatment for atherosclerotic cardiovascular disease by addressing two independent drivers of cardiovascular risk. Our proprietary delivery technology, Nuvec® (THAT-003), offers the potential to overcome the fundamental challenges of RNA delivery, enabling targeted, scalable RNA therapeutics.
For further information visit www.thaliatx.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 9 hours ago Johnson Matthey
- 10 hours ago Galliford Try
- 10 hours ago Galliford Try
- 10 hours ago Centrica
- 11 hours ago Smith & Nephew